BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bertani L, Caviglia GP, Antonioli L, Pellicano R, Fagoonee S, Astegiano M, Saracco GM, Bugianesi E, Blandizzi C, Costa F, Ribaldone DG. Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. J Clin Med 2020;9:E1323. [PMID: 32370274 DOI: 10.3390/jcm9051323] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Cusato J, Bertani L, Antonucci M, Tomasello C, Caviglia GP, Dibitetto S, Massano A, Mangia M, Mula J, Ceccarelli L, Costa F, Zanzi F, Astegiano M, Ribaldone DG, D'Avolio A. Vitamin D-Related Genetics as Predictive Biomarker of Clinical Remission in Adalimumab-Treated Patients Affected by Crohn's Disease: A Pilot Study. Pharmaceuticals (Basel) 2021;14:1230. [PMID: 34959633 DOI: 10.3390/ph14121230] [Reference Citation Analysis]
2 Gonzalez-vivo M, Lund Tiirikainen MK, Andreu M, Fernandez-clotet A, López-garcía A, Murciano Gonzalo F, Abril Rodriguez L, de Jesús-gil C, Ruiz-romeu E, Sans-de San Nicolàs L, Santamaria-babí LF, Márquez-mosquera L. Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis. Front Med 2022;9:837294. [DOI: 10.3389/fmed.2022.837294] [Reference Citation Analysis]
3 Elhag DA, Kumar M, Saadaoui M, Akobeng AK, Al-mudahka F, Elawad M, Al Khodor S. Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic Response. IJMS 2022;23:6966. [DOI: 10.3390/ijms23136966] [Reference Citation Analysis]
4 Chen Y, Li H, Feng Q, Shen J. Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn's Disease Patients. Front Pharmacol 2021;12:654985. [PMID: 33986682 DOI: 10.3389/fphar.2021.654985] [Reference Citation Analysis]
5 Durazzo M, Ferro A, Fagoonee S, Pellicano R. Trends in the Comprehension and Management of Gastrointestinal Tract Disorders. J Clin Med 2022;11:1730. [PMID: 35330054 DOI: 10.3390/jcm11061730] [Reference Citation Analysis]
6 Caviglia GP, De Blasio F, Vernero M, Armandi A, Rosso C, Saracco GM, Bugianesi E, Astegiano M, Ribaldone DG. Efficacy of a Preparation Based on Calcium Butyrate, Bifidobacterium bifidum, Bifidobacterium lactis, and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study. J Clin Med 2021;10:4961. [PMID: 34768480 DOI: 10.3390/jcm10214961] [Reference Citation Analysis]
7 Bertani L, Barberio B, Fornili M, Antonioli L, Zanzi F, Casadei C, Benvenuti L, Facchin S, D'antongiovanni V, Lorenzon G, Ceccarelli L, Baglietto L, de Bortoli N, Bellini M, Costa F, Savarino EV, Fornai M. Serum oncostatin M predicts mucosal healing in patients with inflammatory bowel diseases treated with anti-TNF, but not vedolizumab. Digestive and Liver Disease 2022. [DOI: 10.1016/j.dld.2022.03.008] [Reference Citation Analysis]
8 Bertani L, Antonioli L, Blandizzi C. Letter: ustekinumab's effectiveness outcomes compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers? Aliment Pharmacol Ther 2020;52:751-2. [PMID: 32886387 DOI: 10.1111/apt.15920] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Caviglia GP, Ribaldone DG, Nicolosi A, Pellicano R. Cytokines and Biologic Therapy in Patients with Inflammatory Bowel Diseases. Gastroenterology Insights 2021;12:443-5. [DOI: 10.3390/gastroent12040042] [Reference Citation Analysis]
10 Brehin C, Dubois D, Dicky O, Breinig S, Oswald E, Serino M. Evolution of Gut Microbiome and Metabolome in Suspected Necrotizing Enterocolitis: A Case-Control Study. J Clin Med 2020;9:E2278. [PMID: 32709038 DOI: 10.3390/jcm9072278] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
11 Caballol B, Gudiño V, Panes J, Salas A. Ulcerative colitis: shedding light on emerging agents and strategies in preclinical and early clinical development. Expert Opin Investig Drugs 2021;:1-16. [PMID: 34365869 DOI: 10.1080/13543784.2021.1965122] [Reference Citation Analysis]
12 Duan L, Cheng S, Li L, Liu Y, Wang D, Liu G. Natural Anti-Inflammatory Compounds as Drug Candidates for Inflammatory Bowel Disease. Front Pharmacol 2021;12:684486. [PMID: 34335253 DOI: 10.3389/fphar.2021.684486] [Reference Citation Analysis]
13 Gubatan J, Keyashian K, Rubin SJS, Wang J, Buckman CA, Sinha S. Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives. Clin Exp Gastroenterol 2021;14:333-42. [PMID: 34466013 DOI: 10.2147/CEG.S293272] [Reference Citation Analysis]
14 Privitera G, Pugliese D, Rapaccini GL, Gasbarrini A, Armuzzi A, Guidi L. Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases. J Clin Med 2021;10:853. [PMID: 33669579 DOI: 10.3390/jcm10040853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]